BOLT
Bolt Biotherapeutics Inc
$
6.600
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.7987
Open
6.610
VWAP
6.66
Vol
21.56K
Mkt Cap
12.65M
Low
6.370
Amount
143.57K
EV/EBITDA(TTM)
--
Total Shares
38.13M
EV
-25.98M
EV/OCF(TTM)
--
P/S(TTM)
36.99
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
751.00K
-34.18%
-6.267
-25.4%
819.75K
-35.71%
-6.133
-23.33%
767.50K
-85.45%
-6.267
-44.05%
Estimates Revision
The market is revising Upward the revenue expectations for Bolt Biotherapeutics, Inc. (BOLT) for FY2025, with the revenue forecasts being adjusted by 24.33% over the past three months. During the same period, the stock price has changed by -15.17%.
Revenue Estimates for FY2025
Revise Upward
+24.33%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-14.05%
In Past 3 Month
Stock Price
Go Down
-15.17%
In Past 3 Month
4 Analyst Rating
506.06% Upside
Wall Street analysts forecast BOLT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BOLT is 40.00 USD with a low forecast of 20.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
3 Hold
0 Sell
Hold
506.06% Upside
Current: 6.600
Low
20.00
Averages
40.00
High
80.00
506.06% Upside
Current: 6.600
Low
20.00
Averages
40.00
High
80.00
Stifel
Stephen Willey
Hold
downgrade
$1
2025-05-13
Reason
Stifel
Stephen Willey
Price Target
$1
2025-05-13
downgrade
Hold
Reason
Stifel
Stephen Willey
Hold
Maintains
$1.5 → $1.25
2025-03-25
Reason
Stifel
Stephen Willey
Price Target
$1.5 → $1.25
2025-03-25
Maintains
Hold
Reason
Stifel lowered the firm's price target on Bolt Biotherapeutics to $1.25 from $1.50 and keeps a Hold rating on the shares. Completion of patient enrollment into the Phase 1 single-agent BDC-3042 dose-escalation trial sets the stage for a medical conference presentation in Q2, but the firm continues to believe the competitive intensity of the CLDN18.2 drug development landscape establishes a high safety/efficacy hurdle, the analyst tells investors.
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2025-03-25
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2025-03-25
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2024-11-13
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2024-11-13
Reiterates
Hold
Reason
HC Wainwright & Co.
Edward White
Hold
Reiterates
n/a
2024-08-15
Reason
HC Wainwright & Co.
Edward White
Price Target
n/a
2024-08-15
Reiterates
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Bolt Biotherapeutics Inc (BOLT.O) is -0.28, compared to its 5-year average forward P/E of -1.70. For a more detailed relative valuation and DCF analysis to assess Bolt Biotherapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.70
Current PE
-0.28
Overvalued PE
0.61
Undervalued PE
-4.01
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.67
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.77
Undervalued EV/EBITDA
-4.10
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
60.88
Current PS
3.12
Overvalued PS
174.03
Undervalued PS
-52.26
Financials
Annual
Quarterly
FY2025Q1
YoY :
-76.83%
1.22M
Total Revenue
FY2025Q1
YoY :
-29.12%
-12.12M
Operating Profit
FY2025Q1
YoY :
+2.12%
-11.04M
Net Income after Tax
FY2025Q1
YoY :
+1.41%
-5.76
EPS - Diluted
FY2025Q1
YoY :
-20.21%
-13.37M
Free Cash Flow
FY2025Q1
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q1
YoY :
+340.72%
-903.44
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
2.5K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
2
1.3M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
2.5K
USD
Months
0-12
0
0.0
USD
Months
BOLT News & Events
Events Timeline
2025-05-12 (ET)
2025-05-12
16:29:24
Bolt Biotherapeutics reports Q1 EPS (29c), consensus (36c)
2025-04-30 (ET)
2025-04-30
16:48:59
Bolt Biotherapeutics announces results for Boltbody ISACs at AACR meeting
2025-03-24 (ET)
2025-03-24
16:25:38
Bolt Biotherapeutics reports Q4 EPS (42c), consensus (35c)
Sign Up For More Events
Sign Up For More Events
News
9.0
04-25NewsfilterBolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
4.0
03-25BenzingaHC Wainwright & Co. Reiterates Neutral on Bolt Biotherapeuticsto Neutral
9.5
03-24NewsfilterBolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
Sign Up For More News
People Also Watch
ELSE
Electro-Sensors Inc
4.850
USD
+3.85%
GOEV
Canoo Inc
0.370
USD
0.00%
COEP
Coeptis Therapeutics Holdings Inc
11.910
USD
-3.25%
COHN
Cohen & Company Inc
12.080
USD
-2.03%
SANW
S&W Seed Co
1.835
USD
-13.03%
OCEA
Ocean Biomedical Inc
0
USD
-87.80%
MEIP
MEI Pharma Inc
6.600
USD
+6.45%
LOCL
Local Bounti Corp
2.930
USD
-5.48%
DUO
Fangdd Network Group Ltd
2.180
USD
-3.11%
PWM
Prestige Wealth Inc
0.440
USD
+1.38%
FAQ
What is Bolt Biotherapeutics Inc (BOLT) stock price today?
The current price of BOLT is 6.6 USD — it has decreased -1.64 % in the last trading day.
What is Bolt Biotherapeutics Inc (BOLT)'s business?
What is the price predicton of BOLT Stock?
What is Bolt Biotherapeutics Inc (BOLT)'s revenue for the last quarter?
What is Bolt Biotherapeutics Inc (BOLT)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Bolt Biotherapeutics Inc (BOLT)'s fundamentals?
How many employees does Bolt Biotherapeutics Inc (BOLT). have?